Oncolytics Biotech (ONCY) Competitors $0.60 -0.01 (-2.31%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.60 0.00 (-0.50%) As of 03/28/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCY vs. LFVN, SOPH, VYGR, RZLT, TNGX, MNPR, MDWD, ALMS, INMB, and TVGNShould you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include LifeVantage (LFVN), SOPHiA GENETICS (SOPH), Voyager Therapeutics (VYGR), Rezolute (RZLT), Tango Therapeutics (TNGX), Monopar Therapeutics (MNPR), MediWound (MDWD), Alumis (ALMS), INmune Bio (INMB), and Tevogen Bio (TVGN). These companies are all part of the "pharmaceutical products" industry. Oncolytics Biotech vs. LifeVantage SOPHiA GENETICS Voyager Therapeutics Rezolute Tango Therapeutics Monopar Therapeutics MediWound Alumis INmune Bio Tevogen Bio LifeVantage (NASDAQ:LFVN) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations. Which has preferable valuation and earnings, LFVN or ONCY? LifeVantage has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifeVantage$212.15M0.85$2.94M$0.5625.75Oncolytics BiotechN/AN/A-$20.56M-$0.30-2.00 Do analysts rate LFVN or ONCY? LifeVantage presently has a consensus price target of $30.50, indicating a potential upside of 111.51%. Oncolytics Biotech has a consensus price target of $4.00, indicating a potential upside of 566.67%. Given Oncolytics Biotech's higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than LifeVantage.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LifeVantage 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Oncolytics Biotech 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in LFVN or ONCY? 35.3% of LifeVantage shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 20.7% of LifeVantage shares are owned by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in LFVN or ONCY? LifeVantage received 63 more outperform votes than Oncolytics Biotech when rated by MarketBeat users. Likewise, 77.97% of users gave LifeVantage an outperform vote while only 68.67% of users gave Oncolytics Biotech an outperform vote. CompanyUnderperformOutperformLifeVantageOutperform Votes22377.97% Underperform Votes6322.03% Oncolytics BiotechOutperform Votes16068.67% Underperform Votes7331.33% Is LFVN or ONCY more profitable? LifeVantage has a net margin of 3.46% compared to Oncolytics Biotech's net margin of 0.00%. LifeVantage's return on equity of 34.29% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets LifeVantage3.46% 34.29% 15.04% Oncolytics Biotech N/A -141.15%-84.73% Does the media refer more to LFVN or ONCY? In the previous week, LifeVantage had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 2 mentions for LifeVantage and 1 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 1.89 beat LifeVantage's score of 1.71 indicating that Oncolytics Biotech is being referred to more favorably in the news media. Company Overall Sentiment LifeVantage Very Positive Oncolytics Biotech Very Positive Which has more volatility and risk, LFVN or ONCY? LifeVantage has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. SummaryLifeVantage beats Oncolytics Biotech on 12 of the 16 factors compared between the two stocks. Remove Ads Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCY vs. The Competition Export to ExcelMetricOncolytics BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.30M$6.91B$5.63B$7.83BDividend YieldN/A2.73%4.57%4.00%P/E Ratio-2.227.1723.3318.67Price / SalesN/A220.47388.4691.01Price / CashN/A65.6738.1634.64Price / Book2.226.396.894.23Net Income-$20.56M$142.12M$3.20B$247.15M7 Day Performance-4.78%-5.06%-2.98%-2.17%1 Month Performance-9.20%-7.49%1.63%-5.68%1 Year Performance-43.40%-10.91%9.45%-0.74% Oncolytics Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCYOncolytics Biotech1.9902 of 5 stars$0.60-2.3%$4.00+566.7%-43.4%$51.30MN/A-2.2230Positive NewsLFVNLifeVantage3.7857 of 5 stars$17.04+0.1%$30.50+79.0%+138.3%$213.87M$212.15M30.43260Positive NewsSOPHSOPHiA GENETICS2.6894 of 5 stars$3.20-0.6%$6.80+112.5%-33.9%$213.40M$65.17M-2.94520Short Interest ↓VYGRVoyager Therapeutics4.6212 of 5 stars$3.89-0.3%$14.86+282.0%-60.8%$212.50M$80.00M5.48100RZLTRezolute2.5668 of 5 stars$3.50-2.8%$24.38+596.4%+14.9%$211.87MN/A-2.8740News CoverageHigh Trading VolumeTNGXTango Therapeutics1.8335 of 5 stars$1.95flat$12.33+532.5%-81.5%$210.81M$42.07M-1.6590Short Interest ↑MNPRMonopar Therapeutics1.1279 of 5 stars$34.23+15.1%$43.00+25.6%+1,084.4%$208.87MN/A-17.3810Gap UpMDWDMediWound1.6624 of 5 stars$19.09+3.0%$31.33+64.1%+11.9%$205.91M$19.72M-6.5880ALMSAlumisN/A$4.33-5.3%$26.57+513.7%N/A$204.47MN/A0.00N/AAnalyst ForecastAnalyst RevisionINMBINmune Bio1.9587 of 5 stars$7.67-3.5%$22.80+197.3%-36.0%$203.95M$42,000.00-3.5210Earnings ReportNews CoverageTVGNTevogen Bio3.1772 of 5 stars$1.16-0.9%$7.10+512.1%-68.0%$203.06MN/A0.003 Remove Ads Related Companies and Tools Related Companies LifeVantage Competitors SOPHiA GENETICS Competitors Voyager Therapeutics Competitors Rezolute Competitors Tango Therapeutics Competitors Monopar Therapeutics Competitors MediWound Competitors Alumis Competitors INmune Bio Competitors Tevogen Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCY) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ONCY Stock Free ONCY Stock Alerts